NEWS RELEASES

Printer Friendly Version View printer-friendly version
<< Back
Fortune Magazine Names Millennium Among 100 Best Companies To Work For

CAMBRIDGE, Mass., January 16, 2013Millennium: The Takeda Oncology Company today announced it has been named among the 100 Best Companies to Work For in the United States by FORTUNE. This is the third consecutive year that Millennium, a wholly owned subsidiary of Japan’s largest pharmaceutical company Takeda Pharmaceutical Company Limited, has been included in the annual ranking. After breaking into the Top 100 list at number 56 in 2011 Millennium has moved up to number 20.

“It’s such an honor to once again be recognized by FORTUNE as one of the Top 100 Companies to work for,” said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. “Being included in this very extraordinary list for the third consecutive year speaks to the importance of our Company values and our employees’ commitment to embracing these values. Respect, diversity and putting the needs of patients first have always been at the core of Millennium and will continue to be our guiding principles.”

“Thanks to companies like Millennium, Massachusetts is a world leader in life sciences and biotechnology, leading the way forward in research and innovative strategies,” said Massachusetts Governor Deval Patrick. “As a creative company that has been successful and continues to grow, this recognition for Millennium is well-deserved.”

Over the past year, Millennium has also been named a top employer by the Boston Globe and Science magazine.

Methodology

To pick the 100 Best Companies to Work For, FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America: 259 firms participated in this year’s survey. More than 277,000 employees at those companies responded to a survey created by the institute, a global research and consulting firm operating in 45 countries around the world. Two-thirds of a company’s score is based on the results of the institute’s Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management’s credibility, job satisfaction, and camaraderie. The other third is based on responses to the institute’s Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, methods of internal communication, training, recognition programs, and diversity efforts. After evaluations are completed, if news about a company comes to light that may significantly damage employees’ faith in management, we may exclude it from the list.  Any company that is at least five years old and has more than 1,000 U.S. employees is eligible.

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/InTheNews.aspx.

Contacts:
Manisha Pai
(617) 551-7877
Manisha.Pai@mpi.com

David Albaugh
(617) 444-4457
David.albaugh@mpi.com